Sharpstone P, Ogg C S, Cameron J S
Br Med J. 1969 May 31;2(5656):535-9. doi: 10.1136/bmj.2.5656.535.
A controlled trial in 20 adult patients with the nephrotic syndrome due to proliferative glomerulonephritis compared the effects of consecutive eight-week courses of treatment with prednisolone in conventional dosage and a low-dose azathioprine-prednisolone combination. Though the azathioprine regimen avoided serious toxicity and produced a statistically significant improvement in creatinine clearance and urine protein excretion, the results were not significantly better than with prednisolone itself and overall were not of great clinical value. Prolongation of the azathioprine-prednisolone treatment to one year was associated with some small improvement in the results.The effectiveness of prednisolone in the nephritic syndrome of adults with minimal renal histological abnormality was confirmed by a complete loss of proteinuria within eight weeks in six out of eight patients and substantial reduction in the other two. These two patients subsequently received azathioprine as well but with equivocal results.
一项针对20名因增殖性肾小球肾炎导致肾病综合征的成年患者的对照试验,比较了常规剂量泼尼松龙连续八周疗程与低剂量硫唑嘌呤 - 泼尼松龙联合治疗的效果。尽管硫唑嘌呤方案避免了严重毒性,并在肌酐清除率和尿蛋白排泄方面产生了统计学上显著的改善,但结果并不比泼尼松龙本身显著更好,总体临床价值不大。将硫唑嘌呤 - 泼尼松龙治疗延长至一年与结果有一些小的改善相关。八名患有最小肾脏组织学异常的成年肾病综合征患者中,有六名在八周内蛋白尿完全消失,另外两名患者蛋白尿大幅减少,这证实了泼尼松龙的有效性。这两名患者随后也接受了硫唑嘌呤治疗,但结果不明确。